ArticleJapanese journal of radiology2026
Long-term results of stereotactic body radiotherapy boost in patients with cervical cancer considered unsuitable for intracavitary brachytherapy.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeAlthough stereotactic body radiotherapy (SBRT) boost represents a promising treatment option for patients with locally advanced cervical cancer who were considered unsuitable for brachytherapy, its long-term efficacy and safety remain unclear. This study assessed long-term oncologic outcomes and late toxicities in a patient cohort from a previous phase I/II trial. MATERIALS AND
methodsThis secondary analysis included 21 patients enrolled in an open-label, multicenter, single-arm, prospective phase I/II trial between January 2016 and October 2020. Patients with cervical cancer considered unsuitable for intracavitary brachytherapy received whole-pelvic radiotherapy (45 Gy in 25 fractions), followed by an SBRT boost to the primary tumor (21 Gy delivered in three consecutive daily fractions). The endpoints of this analysis included long-term oncological outcomes and late radiotherapy-related toxicities.
resultsThe cohort comprised 21 patients, of whom 52% were aged ≥ 75 years, 81% had clinical stage III disease, and 43% had a maximum primary tumor size ≥ 70 mm. The median follow-up was 61.1 months (range, 10.4-111.0) for all patients and 71.9 months (range, 60.0-111.0) for surviving patients. The 5-year loco-regional control, progression-free survival, and overall survival rates were 84%, 62%, and 62%, respectively. Grade 3 late toxicity occurred in one patient (urinary tract obstruction), and no grade 4-5 toxicities were observed. Six patients experienced grade 2 late toxicities (proctitis, n = 3; fractures, n = 3).
conclusionThis secondary analysis demonstrated encouraging long-term oncologic outcomes and an acceptable long-term safety profile following SBRT boost. These findings suggest that SBRT may represent a feasible treatment approach in carefully selected patients with locally advanced cervical cancer who are unable or unwilling to undergo brachytherapy.
Indexed as
Identifiers
42828693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.